CD274 and lung carcinoma: This notion is reinforced by our intensive retrospective analysis data from four independent cohorts of patients with lung cancer receiving anti-PD-(L)1 therapy, which showed that preDN-Temhi patients exhibited poorer clinical responses compared with preDN-Temlo patients.